Medincell and AIC Unveil New Positive Phase 3 Results for mdc-CWM: Major Subgroup Analysis Shows Reduced Pain and Opioid Use, and Accelerated Rehabilitation following Total Knee Replacemen...
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm
Check Earnings Report
US:NYSE Investor Relations:
ir.tevapharm.com
Company Research
Source: Yahoo! Finance
over 70% of the trial population (108 out of 151), revealed the following benefits when comparing patients treated with F14/mdc-CWM (n=51) to those in the control group (n=57) 70% reduction in the number of opioid users at 3 months post-surgery, 28% reduction in the total quantity of opioids consumed during the first 3 months post-surgery, Lower daily knee pain over the endpoints of 3 and 7 days, 2 and 6 weeks, and 3 months post-surgery, Range of motion (ROM) milestone (100 degrees) achieved significantly faster, Significant improvements across multiple, independent assessments of pain, inflammation and function. The analysis of this large subgroup of patients undergoing their first TKR revealed a consistently greater treatment effect compared to the overall study population which also included patients receiving a second TKR. This subgroup of patients will be the primary focus of future clinical development, planned for 2025, provided FDA agreement. ACCESS HERE THE CO
Show less
Read more
Impact Snapshot
Event Time:
TEVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TEVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TEVA alerts
High impacting Teva Pharmaceutical Industries Limited American Depositary Shares news events
Weekly update
A roundup of the hottest topics
TEVA
News
- Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025GlobeNewswire
- My Top 10 Portfolio Holdings for 2025 [Yahoo! Finance]Yahoo! Finance
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Teva Pharmaceutical Industries Limited (NYSE: TEVA) had its price target raised by analysts at Barclays PLC from $25.00 to $28.00. They now have an "overweight" rating on the stock.MarketBeat
- Strength Seen in Teva Pharmaceutical Industries (TEVA): Can Its 26.5% Jump Turn into More Strength? [Yahoo! Finance]Yahoo! Finance
TEVA
Earnings
- 11/6/24 - Beat
TEVA
Sec Filings
- 12/20/24 - Form 144
- 12/4/24 - Form 4
- 12/4/24 - Form 3
- TEVA's page on the SEC website